Saturday, July 4, 2015

Quaker BioVentures launches 2d fund

  Quaker BioVentures, Philadelphia, said Friday it had raised $420 million to close its second venture-capital fund.
  That follows an earlier $220 million fund, set up in 2003, which in its first four years returned 23 cents for&n

Quaker BioVentures launches 2d fund

0 comments

  Quaker BioVentures, Philadelphia, said Friday it had raised $420 million to close its second venture-capital fund.
  That follows an earlier $220 million fund, set up in 2003, which in its first four years returned 23 cents for every dollar invested, according to the Pennsylvania State Employees' Retirement System, a Quaker investor.
  Quaker focuses on companies in the "mid-Atlantic" region, which has expanded over the past five years to include companies as far north as Connecticut and as far south as Charleston.
  That region "continues to lag in the pace of life sciences venture investment, even though it is home to many of the world's largest pharmaceutical companies, leading research institutions and government agencies," cofounder Sherrill Neff said in a statement.
  The new fund has so far put money into antipsychotic drugmaker Argolyn BioScience, Charleston, S.C.; insulin developer Diasome Pharmaceuticals, Conshohocken; specialty-drug marketer EKR Therapeutics, Cedar Knoll, N.J.; eye-treatment maker Optherion Inc., New Haven, Conn.; and lung-treatment maker Transave, Monmouth Junction, N.J.

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog

Joseph N. DiStefano
Also on Philly.com:
letter icon Newsletter